MX2017016337A - Tratamiento de carcinoma de linea media nut. - Google Patents

Tratamiento de carcinoma de linea media nut.

Info

Publication number
MX2017016337A
MX2017016337A MX2017016337A MX2017016337A MX2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A MX 2017016337 A MX2017016337 A MX 2017016337A
Authority
MX
Mexico
Prior art keywords
nut line
carcinoma treatment
bromodomain inhibitor
medium nut
nmc
Prior art date
Application number
MX2017016337A
Other languages
English (en)
Spanish (es)
Inventor
B Landau Steven
H Kagey Michael
Original Assignee
Tensha Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tensha Therapeutics Inc filed Critical Tensha Therapeutics Inc
Publication of MX2017016337A publication Critical patent/MX2017016337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2017016337A 2015-06-26 2016-06-24 Tratamiento de carcinoma de linea media nut. MX2017016337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26
PCT/US2016/039270 WO2016210275A1 (en) 2015-06-26 2016-06-24 Treatment of nut midline carcinoma

Publications (1)

Publication Number Publication Date
MX2017016337A true MX2017016337A (es) 2018-11-22

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016337A MX2017016337A (es) 2015-06-26 2016-06-24 Tratamiento de carcinoma de linea media nut.

Country Status (14)

Country Link
US (1) US20180193350A1 (enExample)
EP (1) EP3314005A1 (enExample)
JP (1) JP2018520124A (enExample)
KR (1) KR20180035785A (enExample)
CN (1) CN107787227A (enExample)
AR (1) AR105124A1 (enExample)
AU (1) AU2016283020A1 (enExample)
BR (1) BR112017028178A2 (enExample)
CA (1) CA2989313A1 (enExample)
HK (1) HK1252062A1 (enExample)
IL (1) IL256186A (enExample)
MA (1) MA42249A (enExample)
MX (1) MX2017016337A (enExample)
WO (1) WO2016210275A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
KR20160130778A (ko) 2014-02-28 2016-11-14 텐샤 세러퓨틱스 인코포레이티드 고인슐린혈증과 관련된 질환의 치료
AU2015339511B2 (en) 2014-10-27 2020-05-14 Tensha Therapeutics, Inc. Bromodomain inhibitors
EP4629984A1 (en) * 2022-12-06 2025-10-15 BioVentures, LLC Development of potent dual hdac/brd4 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US8476260B2 (en) 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
SI2496582T1 (sl) 2009-11-05 2016-04-29 Glaxosmithkline Llc Corporation Service Company Benzodiazepinski inhibitor bromodomene
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
EP2496580B1 (en) 2009-11-05 2013-12-11 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
MX384074B (es) * 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
KR20160130778A (ko) 2014-02-28 2016-11-14 텐샤 세러퓨틱스 인코포레이티드 고인슐린혈증과 관련된 질환의 치료

Also Published As

Publication number Publication date
IL256186A (en) 2018-02-28
BR112017028178A2 (en) 2018-08-28
AR105124A1 (es) 2017-09-06
WO2016210275A1 (en) 2016-12-29
CA2989313A1 (en) 2016-12-29
MA42249A (fr) 2018-05-02
AU2016283020A1 (en) 2018-01-04
US20180193350A1 (en) 2018-07-12
JP2018520124A (ja) 2018-07-26
EP3314005A1 (en) 2018-05-02
KR20180035785A (ko) 2018-04-06
CN107787227A (zh) 2018-03-09
HK1252062A1 (zh) 2019-05-10

Similar Documents

Publication Publication Date Title
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
MX2017005555A (es) Inhibidores del bromodominio.
MX2018003824A (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control.
EA201790398A1 (ru) Способы лечения заболевания печени
MX2017016868A (es) Composiciones y metods para inhibir actividad de arginasa.
CL2016000959A1 (es) Adenovirus oncolíticos armados con genes heterologos
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
EA201690987A1 (ru) Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
CO2017012988A2 (es) Agentes, usos y métodos para el tratamiento
MX2018001737A (es) Mecanismo de resistencia a inhibidores de bromodominio bet.
EA201790845A1 (ru) Способ лечения рака
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
BR112017000852A2 (pt) ?aparelho e método para gerar um sinal melhorado utilizando enchimento de ruído independente?.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
ECSP20082339A (es) Moduladores de la expresión de apol1
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
MX382996B (es) Inhibidores de pcna
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
EA201890118A1 (ru) Способ обработки молока
EP4324477A3 (en) Oxabicycloheptanes for modulation of immune response
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.